RTTNews BiotechQwen · 实盘不做把握 3/10不做原因:无增量信息
北京时间·🕒 发布 22:33:37·⟳ 抓取 22:45:21 +11m44s·⚡ 决策 08-27 22:46:30 +1m09s·61.1 天前
Celularity宣布与MuseCell Innovations建立Dezawa MuseCells美国制造合作，五年潜在采购额超3亿美元
同一具体催化（Celularity×MuseCell Innovations制造合作）已于2026-08-27 14:10 UTC被处理，结论为不做。本条来源（RTTNews Biotech）内容与已处理记录完全一致，无新增金额、指引修正、官方确认或监管进展等足以改变结论的事实。前次处理已充分评估：名义五年潜在采购非确定订单、产品未获FDA批准、股价已盘中涨31.75%并从盘前高点回落、Nasdaq迟交10-Q不合规背景。
📄 原文RTTNews Biotech↗ 原文
Celularity Expands Cellular Medicine Manufacturing With MuseCell Innovations Partnership; Stock
Celularity Inc. (CELU), a longevity-focused regenerative and cellular medicine company, announced a U.S. manufacturing…
不做 Celularity Inc.（CELU.US）
重复消息：同一具体催化（Celularity×MuseCell Innovations制造合作）已于14:10 UTC被处理并判定不做。本条无新增金额、指引修正或官方确认。前次评估结论：名义五年$300M为MCI预测上限非确定订单、产品未获FDA批准、股价已盘中涨超30%后回落、Nasdaq迟交10-Q不合规背景，风险回报不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Celularity宣布与MuseCell Innovations的制造合作，名义五年采购超3亿美元，但该金额为基于MCI预测的潜在上限而非确定订单，产品未获FDA批准。股价在消息公布前已大涨（盘中+31.75%后回落），叠加Nasdaq迟交10-Q不合规通知背景，风险回报不足。该催化已于35分钟前被完整研判并判定不做，本条为同一事件的重复来源，无新增事实。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 medium · price-in 风险 high ↗
主要风险
- 五年$300M为MCI单方预测上限，非确定合同，实际采购可能远低于此
- CELU存在Nasdaq迟交10-Q不合规通知，合规风险悬而未决
先例如何影响了这次决策
对本次决策的影响:因判定为重复消息，未进入先例研究阶段
方向:无先例
涨幅量级:无先例
形态:无先例
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- fetch_decision_experience 成功 stock_tools HTTP · 308 ms
{ - search_processed_events 成功 stock_tools HTTP · 988 ms
{"result": "search_processed_events:agent query=`celu dezawa musecells | celularity $300 million manufacturing collaboration | celularity musecell innovations manufacturing partnership`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.9/72 小时、11876 条本臂决策(完整)，返回 3 条候选。\n• 08-27 14:10 UTC(CST 22:10) [ticker] 不做 CELU.US (n
原文全文
展开原文 · 2,441 字
Celularity Inc. (CELU), a longevity-focused regenerative and cellular medicine company, announced a U.S. manufacturing collaboration with MuseCell Innovations (MCI) to establish production of Dezawa MuseCells (DMCs) at Celularity's Florham Park, New Jersey facility.
The initial program will establish U.S. manufacturing capabilities for MCI-authenticated DMC preparations using qualified perinatal starting materials and the licensed Dezawa Method.
The collaboration will also cover manufacturing of DMC-derived products, including Dezawa MuseExosomes and Dezawa MuseSecretome.
The parties intend to expand the manufacturing relationship to additional products and programs following successful completion of the initial project.
Based on current market conditions and MCI's projections, the expanded relationship could generate more than $300 million in aggregate purchases from Celularity over the next five years.
Celularity operates a 147,215-square-foot purpose-built facility in Florham Park, including a cGMP-ready manufacturing center with nine Grade C/ISO 7 and six Grade D/ISO 8 manufacturing suites designed for commercial production of cellular therapies and advanced biomaterials.
The broader collaboration is anticipated to create more than 200 high-tech employment opportunities at the Florham Park site across biomanufacturing, quality control, engineering and support functions.
MCI's Dezawa MuseCell platform is based on discoveries by Professor Mari Dezawa and encompasses Dezawa MuseCells, Dezawa MuseExosomes and Dezawa MuseSecretome. The platform is supported by more than 170 peer-reviewed publications and has been evaluated in multiple human clinical studies.
Celularity said the collaboration expands the utilization of its manufacturing infrastructure and cellular medicine expertise while it continues advancing its proprietary programs, including cenplacel-L, its placental-derived allogeneic cell therapy.
CELU has traded between $0.56 and $ 4.00 over the last year. Currently, the stock is trading at $1.48 up 64.70%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
The initial program will establish U.S. manufacturing capabilities for MCI-authenticated DMC preparations using qualified perinatal starting materials and the licensed Dezawa Method.
The collaboration will also cover manufacturing of DMC-derived products, including Dezawa MuseExosomes and Dezawa MuseSecretome.
The parties intend to expand the manufacturing relationship to additional products and programs following successful completion of the initial project.
Based on current market conditions and MCI's projections, the expanded relationship could generate more than $300 million in aggregate purchases from Celularity over the next five years.
Celularity operates a 147,215-square-foot purpose-built facility in Florham Park, including a cGMP-ready manufacturing center with nine Grade C/ISO 7 and six Grade D/ISO 8 manufacturing suites designed for commercial production of cellular therapies and advanced biomaterials.
The broader collaboration is anticipated to create more than 200 high-tech employment opportunities at the Florham Park site across biomanufacturing, quality control, engineering and support functions.
MCI's Dezawa MuseCell platform is based on discoveries by Professor Mari Dezawa and encompasses Dezawa MuseCells, Dezawa MuseExosomes and Dezawa MuseSecretome. The platform is supported by more than 170 peer-reviewed publications and has been evaluated in multiple human clinical studies.
Celularity said the collaboration expands the utilization of its manufacturing infrastructure and cellular medicine expertise while it continues advancing its proprietary programs, including cenplacel-L, its placental-derived allogeneic cell therapy.
CELU has traded between $0.56 and $ 4.00 over the last year. Currently, the stock is trading at $1.48 up 64.70%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。